{"id":51060,"date":"2022-11-21T04:02:16","date_gmt":"2022-11-21T03:02:16","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/elpiscience-announces-studies-presented-at-sitc-2022-annual-meeting\/"},"modified":"2022-11-21T04:02:16","modified_gmt":"2022-11-21T03:02:16","slug":"elpiscience-announces-studies-presented-at-sitc-2022-annual-meeting","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/elpiscience-announces-studies-presented-at-sitc-2022-annual-meeting\/","title":{"rendered":"Elpiscience Announces Studies Presented at SITC 2022 Annual Meeting"},"content":{"rendered":"<div>\n<p>SHANGHAI &amp; SUZHOU, China &amp; GERMANTOWN, Md.&#8211;(BUSINESS WIRE)&#8211;Elpiscience Biopharmaceuticals, Inc. (\u201cElpiscience\u201d), a clinical-stage biopharmaceutical company focused on developing next-generation immunotherapies to benefit cancer patients worldwide, presented positive studies for its innovative immunotherapeutic molecules at the SITC 2022 Annual Meeting, including anti-SIRP\u03b1 monoclonal antibody ES004, PD-L1\/SIRP\u03b1 bispecific antibody ES019, anti-LILRB2 monoclonal antibody ES009, anti-SIGLEC15 antibody ES012, and anti-LAG3 monoclonal antibody ES005.\n<\/p>\n<p>\nStudy highlights:\n<\/p>\n<p>\n<strong>1. Title: Treatment of anti-SIRP\u03b1 in combination with anti-TAA exerts superior anti-tumor activity<br \/>\n<br \/><\/strong>Abstract No.: 793\n<\/p>\n<p>\nSIRP\u03b1 is an inhibitory receptor expressed mainly on myeloid cells and dendritic cells. Ligation of CD47 to SIRP\u03b1 delivers a \u201cdon\u2019t eat me\u201d signal to suppress macrophage phagocytosis. Tumor cells frequently overexpress CD47 to evade macrophage-mediated destruction. Anti-SIRP\u03b1 mAb ES004 potently potentiates antibody dependent cellular phagocytosis (ADCP) activity of antibodies against tumor associated antigens (TAAs) <i>in vitro<\/i> and <i>in vivo<\/i>.\n<\/p>\n<p>\nHighlights:\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nES004 recognizes pan-allele human SIRP\u03b1 with high affinity\n<\/li>\n<li>\nES004 binds to a unique epitope on the CD47 binding domain of SIRP\u03b1\n<\/li>\n<li>\nES004 potently blocks CD47-SIRP\u03b1 interaction and CD47 induced SIRP\u03b1 signaling\n<\/li>\n<li>\nES004 effectively potentiates pan-allelic macrophage phagocytosis of tumor cells\n<\/li>\n<li>\nES004 has no negative impact on T cell activation\n<\/li>\n<li>\nES004 enhances anti-tumor activity in combination with anti-Claudin18.2 in MC38\/hCLDN18.2 syngenetic tumor model\n<\/li>\n<li>\nES004 has demonstrated favorable PK, full target occupancy and excellent safety profile in cynomolgus monkeys.\n<\/li>\n<\/ul>\n<p>\n<strong>2. Title: Dual targeting of innate and adaptive immune checkpoints with a PD-L1\/SIRP\u03b1 bispecific macrophage engager to promote anti-tumor activity<br \/>\n<br \/><\/strong>Abstract No.: 1211\n<\/p>\n<p>\nThe anti-PDL1\/SIRP\u03b1 bispecific antibody ES019, designed for tumor cell and immune cell dual targeting, is capable of reactivating macrophages and T cells to kill cancer cells with the potential to overcome the limitations of traditional anti-PD1 therapies and has demonstrated significantly enhanced tumor therapeutic efficacy and specificity versus combo or monotherapies.\n<\/p>\n<p>\nHighlights:\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nES019 phagocytosis activity is corrected with PD-L1 level on tumor cells\n<\/li>\n<li>\nES019 leads to better phagocytosis capability of tumor cells by M2-like than M1-like macrophage\n<\/li>\n<li>\nES019 activates T cells without induction of phagocytosis of T cells\n<\/li>\n<li>\nES019 shows favorable PK in mouse model\n<\/li>\n<li>\nES019 demonstrates single agent anti-tumor efficacy in animal model\n<\/li>\n<\/ul>\n<p>\n<strong>3. Title: ES009, a LILRB2-specific blocking antibody, reprograms myeloid cells into pro-inflammation phenotype and potentiates T cell activation<br \/>\n<br \/><\/strong>Abstract No.: 1062\n<\/p>\n<p>\nLILRB2 is predominantly expressed in myeloid lineage cells. Human LILRB2 broadly binds to multiple ligands and contributes to immune suppression in the tumor microenvironment (TME). Anti-LILRB2 mAb ES009 has demonstrated superior effects in converting immunosuppressive myeloid cells into pro-inflammation phenotypes in <i>in vitro <\/i>and <i>ex vivo <\/i>models.\n<\/p>\n<p>\nHighlights:\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nES009 specifically binds human LILRB2 with high affinity\n<\/li>\n<li>\nES009 binds to a unique epitope on D1 domain of LILRB2\n<\/li>\n<li>\nES009 potently blocks LILRB2 binding to multiple ligands\n<\/li>\n<li>\nES009 promotes monocytes and monocytes derived DCs into a pro-inflammatory status\n<\/li>\n<li>\nES009 effectively reprograms human monocyte derived M2 macrophages into pro-inflammation M1 phenotypes\n<\/li>\n<li>\nES009 effectively relives T cells from M2 macrophages mediated suppression\n<\/li>\n<li>\nES009 converts primary macrophages in malignant ascites in ovarian cancer patients into a pro-inflammatory status\n<\/li>\n<\/ul>\n<p>\n<strong>4. Title: SIGLEC15 induces monocyte apoptosis and an SIGLEC15 antibody ES012 reverses myeloid cells driven immunosuppression<br \/>\n<br \/><\/strong>Abstract No.: 1401\n<\/p>\n<p>\nSIGLEC15 is a glycan-recognition proteins belonging to the SIGLEC family and is highly expressed on TAM and many tumor cells. It\u2019s reported that SIGLEC15 inhibits T cell activity via its binding to an unknown receptor on T cells. Elpiscience has identified a novel function of SIGLEC15 that SIGLEC15 can induce monocyte apoptosis and its inhibitory effect on T cell function is indirect. Based on this newly discovered SIGLEC15 biology, we have developed a potent, functional anti-SIGLEC15 mAb ES012 that has great potential to reverse immune suppression in TME to promote anti-tumor immunity.\n<\/p>\n<p>\nHighlight:\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nSIGLEC15 induces monocyte apoptosis, which is dependent on sialic acid binding and mediated via caspase-3\n<\/li>\n<li>\nSIGLEC15 inhibits T cell function via myeloid cells but not by directly binding to T cells\n<\/li>\n<li>\nES012 is a high affinity anti-SIGLEC15 monoclonal antibody.\n<\/li>\n<li>\nES012 can rescue monocyte apoptosis and inhibit T cells by SIGLEC15.\n<\/li>\n<li>\nES012 showed superior anti-tumor efficacy and better PK profile than benchmark antibody in preclinical model\n<\/li>\n<\/ul>\n<p>\n<strong>5. Title: ES005, a high affinity anti-LAG3 monoclonal antibody, inhibits the interactions between LAG3 and multiple ligands and enhances anti-tumor activity of T cells in preclinical models<br \/>\n<br \/><\/strong>Abstract No.: 426\n<\/p>\n<p>\nLAG3 plays an important role in regulating immune homeostasis with multiple biological activities related to T cell functions. Anti-LAG3 mAb ES005 has demonstrated significant tumor growth inhibition in <i>in vivo<\/i> mouse tumor models, and showed excellent PK and safety profile in NHPs, indicating great potential to be used as next-generation immune checkpoint inhibitor in cancer treatment.\n<\/p>\n<p>\nHighlights:\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nES005 is a high affinity and cynomolgus reactive anti-LAG3 mAb\n<\/li>\n<li>\nES005 binds to a unique epitope on LAG3 D1 domain\n<\/li>\n<li>\nES005 potently blocks LAG3 binding to multiple ligands including FGL-1\n<\/li>\n<li>\nES005 effectively upregulates NFAT reporter gene transcription via blocking LAG3\/MHC-II interaction\n<\/li>\n<li>\nES005 effectively reverses LAG3 driven inhibition of T cell activation\n<\/li>\n<li>\nES005 monotherapy potently inhibits tumor growth in EMT6 syngeneic tumor model\n<\/li>\n<li>\nES005 was well tolerated in cynomolgus monkeys with favorable PK Profile\n<\/li>\n<\/ul>\n<p>\nTo learn more about the studies, please visit Elpiscience official website <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.elpiscience.com&amp;esheet=52972647&amp;newsitemid=20221118005140&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.elpiscience.com&amp;index=1&amp;md5=8e04393708ef9e25520e6d0dd08705f3\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/www.elpiscience.com<\/a>\n<\/p>\n<p>\n<b>About Elpiscience:<\/b>\n<\/p>\n<p>\nElpiscience is a clinical-stage biopharmaceutical company focused on developing next-generation immunotherapy to benefit cancer patients worldwide. The Company has a robust pipeline of globally innovative cancer immunotherapies covering wide range of oncology targets and multiple proprietary technologies to enable discovery including its Bispecific Macrophage Engager (BiME<sup>\u00ae<\/sup>) antibody platform for solid tumors, human antibody Fab library ElpiSource<sup>TM <\/sup>and H-L interchain disulfide bond engineering BsAb platform Acebody<sup>TM<\/sup>.\n<\/p>\n<p>\nFounded and managed by a team of biotechnology industry leaders and scientists, Elpiscience is supported by a world-class Scientific Advisory Board and high-quality investors including, Lilly Asia Ventures, GL Ventures, Hyfinity Investments, Greater Bay Area Homeland Development Fund, CDH, DYEE Capital and Cormorant Asset Management.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>BD inquiries:<\/b><br \/><a target=\"_blank\" href=\"&#109;&#x61;&#105;&#x6c;&#116;&#x6f;&#58;&#x42;&#68;&#x40;&#101;&#x6c;p&#x69;s&#x63;i&#x65;n&#x63;e&#x2e;c&#111;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#66;D&#x40;e&#x6c;&#112;&#x69;&#115;&#x63;&#105;e&#x6e;c&#x65;&#46;&#x63;&#111;&#x6d;<\/a><span class=\"bwuline\"> <\/span>\n<\/p>\n<p>\n<b><span class=\"bwuline\">I<\/span>nvestor inquiries:<\/b><br \/><a target=\"_blank\" href=\"&#x6d;&#x61;&#x69;&#108;&#116;o:&#x49;&#x52;&#x40;&#101;&#108;pi&#x73;&#x63;&#x69;&#101;&#110;ce&#x2e;&#x63;&#x6f;&#109;\" rel=\"nofollow noopener\" shape=\"rect\">I&#82;&#64;&#x65;&#x6c;p&#105;&#115;&#x63;&#x69;&#x65;n&#99;&#101;&#x2e;&#x63;om<\/a>\n<\/p>\n<p>\n<b>Media inquiries:<\/b><br \/><a target=\"_blank\" href=\"&#x6d;&#x61;&#x69;&#x6c;&#x74;&#x6f;&#x3a;&#x50;&#x52;&#x40;&#x65;&#x6c;&#x70;&#x69;&#115;&#99;&#105;&#101;&#110;&#99;&#101;&#46;&#99;&#111;&#109;\" rel=\"nofollow noopener\" shape=\"rect\">&#x50;&#82;&#64;&#x65;&#x6c;&#112;i&#x73;&#99;i&#x65;&#x6e;&#99;e&#x2e;&#99;o&#x6d;<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>SHANGHAI &amp; SUZHOU, China &amp; GERMANTOWN, Md.&#8211;(BUSINESS WIRE)&#8211;Elpiscience Biopharmaceuticals, Inc. (\u201cElpiscience\u201d), a clinical-stage biopharmaceutical company focused on developing next-generation immunotherapies to benefit cancer patients worldwide, presented positive studies for its innovative immunotherapeutic molecules at the SITC 2022 Annual Meeting, including anti-SIRP\u03b1 monoclonal antibody ES004, PD-L1\/SIRP\u03b1 bispecific antibody ES019, anti-LILRB2 monoclonal antibody ES009, anti-SIGLEC15 antibody ES012, &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/elpiscience-announces-studies-presented-at-sitc-2022-annual-meeting\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-51060","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Elpiscience Announces Studies Presented at SITC 2022 Annual Meeting - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/elpiscience-announces-studies-presented-at-sitc-2022-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Elpiscience Announces Studies Presented at SITC 2022 Annual Meeting - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"SHANGHAI &amp; SUZHOU, China &amp; GERMANTOWN, Md.&#8211;(BUSINESS WIRE)&#8211;Elpiscience Biopharmaceuticals, Inc. (\u201cElpiscience\u201d), a clinical-stage biopharmaceutical company focused on developing next-generation immunotherapies to benefit cancer patients worldwide, presented positive studies for its innovative immunotherapeutic molecules at the SITC 2022 Annual Meeting, including anti-SIRP\u03b1 monoclonal antibody ES004, PD-L1\/SIRP\u03b1 bispecific antibody ES019, anti-LILRB2 monoclonal antibody ES009, anti-SIGLEC15 antibody ES012, ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/elpiscience-announces-studies-presented-at-sitc-2022-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-21T03:02:16+00:00\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/elpiscience-announces-studies-presented-at-sitc-2022-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/elpiscience-announces-studies-presented-at-sitc-2022-annual-meeting\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Elpiscience Announces Studies Presented at SITC 2022 Annual Meeting\",\"datePublished\":\"2022-11-21T03:02:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/elpiscience-announces-studies-presented-at-sitc-2022-annual-meeting\\\/\"},\"wordCount\":978,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/elpiscience-announces-studies-presented-at-sitc-2022-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/elpiscience-announces-studies-presented-at-sitc-2022-annual-meeting\\\/\",\"name\":\"Elpiscience Announces Studies Presented at SITC 2022 Annual Meeting - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"datePublished\":\"2022-11-21T03:02:16+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/elpiscience-announces-studies-presented-at-sitc-2022-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/elpiscience-announces-studies-presented-at-sitc-2022-annual-meeting\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/elpiscience-announces-studies-presented-at-sitc-2022-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Elpiscience Announces Studies Presented at SITC 2022 Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Elpiscience Announces Studies Presented at SITC 2022 Annual Meeting - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/elpiscience-announces-studies-presented-at-sitc-2022-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Elpiscience Announces Studies Presented at SITC 2022 Annual Meeting - Pharma Trend","og_description":"SHANGHAI &amp; SUZHOU, China &amp; GERMANTOWN, Md.&#8211;(BUSINESS WIRE)&#8211;Elpiscience Biopharmaceuticals, Inc. (\u201cElpiscience\u201d), a clinical-stage biopharmaceutical company focused on developing next-generation immunotherapies to benefit cancer patients worldwide, presented positive studies for its innovative immunotherapeutic molecules at the SITC 2022 Annual Meeting, including anti-SIRP\u03b1 monoclonal antibody ES004, PD-L1\/SIRP\u03b1 bispecific antibody ES019, anti-LILRB2 monoclonal antibody ES009, anti-SIGLEC15 antibody ES012, ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/elpiscience-announces-studies-presented-at-sitc-2022-annual-meeting\/","og_site_name":"Pharma Trend","article_published_time":"2022-11-21T03:02:16+00:00","author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/elpiscience-announces-studies-presented-at-sitc-2022-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/elpiscience-announces-studies-presented-at-sitc-2022-annual-meeting\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Elpiscience Announces Studies Presented at SITC 2022 Annual Meeting","datePublished":"2022-11-21T03:02:16+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/elpiscience-announces-studies-presented-at-sitc-2022-annual-meeting\/"},"wordCount":978,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/elpiscience-announces-studies-presented-at-sitc-2022-annual-meeting\/","url":"https:\/\/pharma-trend.com\/en\/elpiscience-announces-studies-presented-at-sitc-2022-annual-meeting\/","name":"Elpiscience Announces Studies Presented at SITC 2022 Annual Meeting - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"datePublished":"2022-11-21T03:02:16+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/elpiscience-announces-studies-presented-at-sitc-2022-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/elpiscience-announces-studies-presented-at-sitc-2022-annual-meeting\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/elpiscience-announces-studies-presented-at-sitc-2022-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Elpiscience Announces Studies Presented at SITC 2022 Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/51060","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=51060"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/51060\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=51060"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=51060"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=51060"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}